Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Duchenne muscular dystrophy (DMD) is a lethal genetic disorder caused by mutations in the dystrophin gene.
• Exon skipping with antisense oligonucleotides (AOs) aims to restore dystrophin production by correcting splicing defects.
• Current AO therapies, like eteplirsen, face challenges regarding efficacy and patient benefit.

Purpose of the Study:

• To design and evaluate novel antisense morpholino oligonucleotides (AOs) for Duchenne muscular dystrophy (DMD) exon 51 skipping.
• To compare the efficacy of newly designed AOs against the established drug eteplirsen.
• To validate the in vivo efficacy of optimized AOs in a relevant animal model.

Main Methods:

• Development of an in silico tool for designing antisense morpholino sequences targeting specific exons.
• In vitro assessment of exon skipping efficiency and dystrophin protein restoration in immortalized DMD muscle cells.
• In vivo validation of the most effective morpholino in mice carrying the human DMD gene.

Main Results:

• Newly designed morpholino AOs demonstrated superior exon 51 skipping efficiency compared to eteplirsen.
• Dystrophin protein expression rescue was significantly enhanced, with up to 12-fold increase in skipping and 7-fold in protein levels.
• The most effective morpholino showed significant in vivo efficacy in a mouse model.

Conclusions:

• Antisense morpholino sequence optimization is crucial for enhancing exon skipping efficacy in DMD.
• The developed in silico tool provides a powerful method for designing next-generation AOs for DMD.
• These findings suggest a more effective therapeutic strategy for Duchenne muscular dystrophy.